演題抄録

International Session(Poster)

開催概要
開催回
第51回・2013年・京都
 

A survey of MET overexpression and amplification in hepatocellular carcinoma

演題番号 : ISP-18

[筆頭演者]
Ho Yeong Lim:1 
[共同演者]
Sujin Lee:1、Jeeyun Lee:1、Cheol-Keun Park:1、Insuk Sohn:1,2、Mao Mao:3、Wang Kai:3

1:Departments of Internal Medicine and Pathology, Samsung Medical Center, Sungkyunkwan University, Korea、2:Samsung Genomic Center, Samsung Medical Center, Korea、3:Oncology Research Unit, Pfizer Inc., USA

 

c-MET is a new potential drug target for treatment of hepatocellular carcinoma (HCC) patients, and recent studies of c-MET inhibitors in HCC patients have shown promising results. In the present study, we investigated the incidence of c-MET overexpression and its prognostic impact.Tumor tissue microarrays were used to detect the expression of c-MET in samples from 287 HCC patients who underwent surgical resection at Samsung Medical Center. We explored the relationships between c-MET overexpression and clinicopathologic features of HCC and investigated recurrence-free survival (RFS) and HCC-specific survival according to the level of c-MET expression. Additionally, we explored the correlation between c-MET protein overexpression, MET mRNA expression and MET copy number variation. Most patients in this study were male (n=297, 82.6%), with Child-Pugh class A liver function (n=286, 99.7%) and hepatitis B viral infection (n=217, 75.6%). c-MET overexpression was observed in 80 patients (27.9%), and it was not associated with Edmondson grade, tumor size, microvascular invasion, major portal vein invasion or AJCC stage. In addition, c-Met expression level did not affect RFS or HCC-specific survival. c-MET expression was weakly correlated with MET copy number variation (r=0.255, P<0.001), but over half of patients with high c-MET expression showed neutral copy number. c-MET IHC expression showed a very weakly but significantly positive correlation with its mRNA expression (r=0.199, P=0.002).In this study, c-MET overexpression did not show a prognostic impact on recurrence or survival in HCC patients with surgical resection. However, 27.9% of HCC patients who had c-MET overexpression are candidates for treatment with c-MET inhibitor.

前へ戻る